[의학신문·일간보사=김상일 기자]Is it due to Daewoong Pharmaceutical-Meditox dispute? Multinational pharmaceutical companies Mertz and Allergan botox imports grew by more than 40%.
As a result of a reanalysis of the’Biopharmaceutical Industry Trend Report’ of the Ministry of Food and Drug Safety and the Korea Biopharmaceutical Association on the 16th, the Daily Newspaper and the Medical Newspaper, Mertz Zeo, imported $5068,000 in 2019, compared to the previous year ($3613,000). With 40.3% growth, it ranked first in earnings.
 |
| ◆ Performance status of major domestic antitoxin imported items <단위 : 천달러, %> |
Subsequently, 50 units of Botox from Korea Allergan were imported by $3,466,000, up 40.3% from the previous year ($2.47 million), and Botox stock also imported $2576,000, up 133% from the previous year ($1.12,000).
Along with this, Ibsen Korea’s sports stock also imported $1297,000, up 56.6% from the previous year ($829,000).
However, the 50 units of the Mertz Zeo democratic unit imported 99,000 dollars, down 83% from the previous year ($597,000).
In addition, Xeomin 100IU became the product that recorded the No. 1 market share in the imported botulinum toxin market for two consecutive years from 2018 to 2019.
Zeomin is the world’s first botulinum toxin that contains only pure neurotoxins and minimizes the possibility of resistance.It is sold in 73 countries around the world with approval from the US FDA, European EMA, and Korea Food and Drug Administration. No research has been reported on the occurrence of resistance even at the number of 3100,000 procedures.
Su-yeon Yoo, CEO of Multz said, “We believe that this growth of Zeomin is the result of excellent resistance safety and natural treatment effects that are in line with the needs and trends of consumers and medical staff who choose botulinum toxin treatment recently.” “Multz will continue to lead the market trend. And I will do my best to become an example of the industry.”
Reporter Kim Sang-il [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>